Evaluation of newly-developed modified diluted prothrombin time reagent in non-valvular atrial fibrillation patients with direct oral anticoagulants: A comparative study with conventional reagents.

Kumano, Osamu; Suzuki, Shinya; Yamazaki, Masako; An, Yoshimori; Yasaka, Masahiro; Ieko, Masahiro

Kumano, Osamu; Suzuki, Shinya; Yamazaki, Masako; An, Yoshimori; Yasaka, Masahiro; Ieko, Masahiro.

Afiliação

Kumano O; Sysmex Corporation, Kobe, Hyogo, Japan.
Suzuki S; Department of Cardiovascular Medicine, The Cardiovascular Institute, Tokyo, Japan.
Yamazaki M; Department of Neurology, Tokyo Women's Medical University, Tokyo, Japan.
An Y; Department of Artificial Intelligence Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan.
Yasaka M; Department of Cardiology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
Ieko M; Department of Cerebrovascular Medicine and Neurology, Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.

Int J Lab Hematol ; 45(1): 119-125, 2023 Feb.

Article em En | MEDLINE | ID: mdl-36114152

Assuntos

Fibrilação Atrial; Rivaroxabana; Humanos; Tempo de Protrombina; Rivaroxabana/uso terapêutico; Fibrilação Atrial/tratamento farmacológico; Inibidores do Fator Xa; Piridonas/uso terapêutico; Anticoagulantes/uso terapêutico

Palavras-chave

apixaban; edoxaban; oral anticoagulant; prothrombin time; rivaroxaban

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fibrilação Atrial / Rivaroxabana Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google